COST-EFFECTIVENESS OF RISEDRONATE VS. GENERIC ALENDRONATE- CONSIDERATION OF CALCIUM SUPPLEMENTS
Author(s)
Werner Moehrke, PhD, Senior Medical Advisor1, Margaret Pasquale, PhD, Senior Health Economist2, Gerd Moeller, MD, Senior Medical Advisor11Procter & Gamble Pharmaceuticals, Schwalbach a.Ts, Germany; 2 Procter & Gamble Pharmaceuticals, Mason, OH, USA
OBJECTIVES: Treatment of post-menopausal osteoporosis with bisphosphonates should be supplemented by adequate amounts of calcium. The objective of this analysis was to assess the cost-effectiveness of the combination package of risedronate plus calcium compared to generic alendronate and calcium supplements in high-risk osteoporotic patients in Germany. METHODS: A validated model (Tosteson, 2001) was used to estimate the impact of therapy on hip and vertebral fractures, costs, and quality adjusted life years (QALYs). The analysis included women 70 years with a BMD T-Score of
Conference/Value in Health Info
2006-10, ISPOR Europe 2006, Copenhagen, Denmark
Value in Health, Vol. 9, No.6 (November/December 2006)
Code
POS7
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Musculoskeletal Disorders